Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26457908 | 0.93 | PDK2 (0.34) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18386054 | 0.91 | ESR1 (0.35) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26807388 | 0.84 | PDK2 (0.35) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18386050 | 0.84 | MEN1 (0.40) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18386051 | 0.83 | PDK2 (0.40) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18708074 | 0.82 | PDK2 (0.33) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26457902 | 0.80 | — | — | |
| SCHEMBL26457910 | 0.78 | PDK2 (0.33) | MAPK1 | |
| SCHEMBL24806473 | 0.77 | PDK2 (0.35) | SMN1; SMN2TDP1ESR1ESR2 | |
| SCHEMBL18386055 | 0.76 | PDK2 (0.39) | MAPK1L3MBTL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11641778-B2 | Compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11641778-B2 | Compound and organic light emitting device comprising same | CRY1, CYP1A1, CRY2 | MAPK1 1507/4885L3MBTL1 1567/4885NPC1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.